These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15939261)

  • 41. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.
    Park JW; Kerbel RS; Kelloff GJ; Barrett JC; Chabner BA; Parkinson DR; Peck J; Ruddon RW; Sigman CC; Slamon DJ
    Clin Cancer Res; 2004 Jun; 10(11):3885-96. PubMed ID: 15173098
    [No Abstract]   [Full Text] [Related]  

  • 42. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs.
    Kelloff GJ; Schilsky RL; Alberts DS; Day RW; Guyton KZ; Pearce HL; Peck JC; Phillips R; Sigman CC
    Clin Cancer Res; 2004 Jun; 10(11):3908-18. PubMed ID: 15173100
    [No Abstract]   [Full Text] [Related]  

  • 44. Individual- and trial-level surrogacy in colorectal cancer.
    Buyse M; Burzykowski T; Michiels S; Carroll K
    Stat Methods Med Res; 2008 Oct; 17(5):467-75. PubMed ID: 18285439
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting angiogenesis with integrative cancer therapies.
    Yance DR; Sagar SM
    Integr Cancer Ther; 2006 Mar; 5(1):9-29. PubMed ID: 16484711
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy.
    Pantaleo MA; Nannini M; Maleddu A; Fanti S; Ambrosini V; Nanni C; Boschi S; Biasco G
    Cancer Treat Rev; 2008 Apr; 34(2):103-21. PubMed ID: 18055120
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Two simple approaches for validating a binary surrogate endpoint using data from multiple trials.
    Baker SG
    Stat Methods Med Res; 2008 Oct; 17(5):505-14. PubMed ID: 18285436
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspective.
    Piedbois P; Miller Croswell J
    Stat Methods Med Res; 2008 Oct; 17(5):519-27. PubMed ID: 18285441
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluating pathophysiologic processes rather than clinical end points in improving therapeutic practice.
    Cohn JN
    J Cardiovasc Pharmacol; 1998; 32 Suppl 3():S38-40. PubMed ID: 9883746
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Statistical evaluation of biomarkers as surrogate endpoints: a literature review.
    Weir CJ; Walley RJ
    Stat Med; 2006 Jan; 25(2):183-203. PubMed ID: 16252272
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Surrogate end points in secondary analyses of cardiovascular trials.
    Buhr KA
    Prog Cardiovasc Dis; 2012; 54(4):343-50. PubMed ID: 22226002
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cancer clinical trial outcomes: any progress in tumour-size assessment?
    Verweij J; Therasse P; Eisenhauer E;
    Eur J Cancer; 2009 Jan; 45(2):225-7. PubMed ID: 19068275
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biomarkers as surrogate endpoints in cancer trials.
    Dunn BK; Akpa E
    Semin Oncol Nurs; 2012 May; 28(2):99-108. PubMed ID: 22542317
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure.
    Konstam MA
    Am J Cardiol; 2005 Sep; 96(6):867-71. PubMed ID: 16169379
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses.
    Voorzanger-Rousselot N; Garnero P
    Cancer Treat Rev; 2007 May; 33(3):230-83. PubMed ID: 17433551
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design of clinical trials of gene therapy in Parkinson disease.
    Lewis TB; Standaert DG
    Exp Neurol; 2008 Jan; 209(1):41-7. PubMed ID: 17920590
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
    Hudis CA; Barlow WE; Costantino JP; Gray RJ; Pritchard KI; Chapman JA; Sparano JA; Hunsberger S; Enos RA; Gelber RD; Zujewski JA
    J Clin Oncol; 2007 May; 25(15):2127-32. PubMed ID: 17513820
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quantifying the treatment effect explained by markers in the presence of measurement error.
    Sarkar S; Qu Y
    Stat Med; 2007 Apr; 26(9):1955-63. PubMed ID: 16981176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.